A filing by the Department of Justice has asked Judge Matthew Kacsmaryk, a Trump appointee who opposes abortion, to block the ...

Digital therapeutics (DTx) developer Hinge Health has published a new prospectus for an initial public offering (IPO) in the ...

Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...

The 'Choose Europe for Science' scheme was revealed by President of the European Commission Ursula Von Der Leyen during a ...

The phase 2 PIVOT-HD trial of Novartis-partnered PTC518 (votoplam) showed that the oral mRNA splicing modifier was able to ...

Frontiers Health returns on Wednesday 8th November, for a three-day meeting of minds in the Italian capital of Rome. On Thursday 9th November, however, the thematic session, ‘Science and ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

Novo Nordisk has pulled ahead in the race to bring the first oral GLP-1 for obesity to market. The company announced Friday ...

Meanwhile, there was more encouraging news for the UK's science base after it emerged that the country's research teams have ...

That is according to the chief executive of the American Association for the Advancement of Science (AAAS), Sudip Parikh, who ...

The US federal government intends to spend $500 million on a project to develop universal vaccines that can protect against multiple virus variants at the same time. That's the conclusion of an ...

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD), setting it on course to become the first non-steroidal ...